Tuesday

BioTech Webinars

Oct. 27th

1

11:00 am – 12:00 pm ET

Where is the growing science and its link to disease leading us in terms of new treatments for patients with unresolved chronic conditions?

Category: Chronic conditions

Michael_Rosenblatt

Chair:
Dr Michael ROSENBLATT M.D.

Chief Medical Officer
Flagship Pioneering, Cambridge, MA

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Liletta_logo

Representative of
Medicines360

Ponda_Motsepe_Ditshego_Amgen_BioTech_Web_1

Ponda Motsepe – Ditshego, MD, MBChB, GEDP
Executive Medical Director
Amgen Bone

Aimovig_logo

Representative of
Amgen

Eric_Pearlman_Eli_Lilly__BioTech_Web_1_Pharna_Web_1

Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs
Eli Lilly and Company

Dan_Cua_Janssen_BioTech_Web_1

Dan Cua, Ph.D.
Vice President
IL-23 Pathway Area Leader for the Immunology Therapeutic Area
Janssen Biotech, Inc.

Rybelsus_logo

Representative of
Novo Nordisk

Dupixent_logo

Representative of
Regeneron and Sanofi

Liletta_logo
Evenity_logo
Aimovig_logo
Emgality_logo
Tremfya_logo
Rybelsus_logo
Dupixent_logo

2

12:00 pm – 1:15 pm ET

Can the foundational biologic understandings now being brought to cancer care be leveraged to secure a targeted, more personalized approach to other conditions?

Category: Cancer, other rare conditions and vaccines

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Javad_Shahidi_Daiichi_BioTech_Web_2

Javad Shahidi, MD, MSc
Vice President, Global Oncology R&D
Daiichi Sankyo

Beth_Ann_Coller_Ervebo_Biotech_Web_2

Beth-Ann Coller, Ph.D.
Executive Director, Global Clinical Development
Merck & Co., Inc

Oxervate_logo

Representative of
Dompé U.S. Inc.

Representative of
Takeda Pharmaceutical Company Limited

Bernard_Delaey_Sanofi_BioTech_Web_2

Bernard Delaey
Regulatory Therapeutic Area Lead
Sanofi

Polivy_logo

Representative of
Genentech, a member of the Roche Group

Cablivi_logo
Polivy_logo
Cablivi_logo
Polivy_logo

3

1:30 pm – 2:45 pm ET

Will progress in therapies that promise a genetic cure for devastating rare diseases lead to similar innovations in patient access to these highcost, high-touch treatments?

Category: Rare Genetic Disorders

Mary-Claire_King

Chair:
Pr Mary-Claire KING

American Cancer Society Professor of Genome Sciences and Medical Genetics
University of Washington

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Inotersen_logo

Representative of
Akcea Therapeutics and Ionis Pharmaceticals

Pushkal_Garg_Alnylam_BioTech_Web_3

Pushkal Garg, MD
Chief Medical Officer
Alnylam

 

Palynziq_logo

Representative of
BioMarin Pharmaceutical, Inc.

Ted_W. Love_GBT_BioTech_Web_3

Ted W. Love, M.D.
President & Chief Executive Officer
Global Blood Therapeutics, Inc.

Petra_Kaufmann_Novartis_BioTech_Web_3

Petra Kaufmann, M.D.
Senior Vice President, Translational Medicine and Clinical Development
Novartis Gene Therapies

 

Inotersen_logo
1594928706GIVLAARI_®_US_4C
Galafold_logo
Palynziq_logo
Ted_W. Love_GBT_BioTech_Web_3
Zolgensma_logo
Onpattro_logo

Stay tuned: new developments are on the way